期刊
CELL REPORTS MEDICINE
卷 2, 期 4, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.xcrm.2021.100227
关键词
-
资金
- European Research Council [335326]
- King's Commercialisation Institute
- UK Medical Research Council [MR/N013700/1]
- Consejo Nacional de Ciencia y Tecnologi'a (CONACyT)
- Cancer Research UK King's Health Partners Centre and Experimental Cancer Medicine Centre at King's College London
- National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London
- European Research Council (ERC) [335326] Funding Source: European Research Council (ERC)
In this study, a new CAR T cell system utilizing hypoxia-sensing technology for selective expression of pan-ErbB targeted CAR within solid tumors was presented. The approach demonstrated anti-tumor efficacy without off-tumor toxicity, showing potential for expansion of CAR T cell target repertoire for treating solid malignancies.
Utilizing T cells expressing chimeric antigen receptors (CARs) to identify and attack solid tumors has proven challenging, in large part because of the lack of tumor-specific targets to direct CAR binding. Tumor selectivity is crucial because on-target, off-tumor activation of CAR T cells can result in potentially lethal toxicities. This study presents a stringent hypoxia-sensing CAR T cell system that achieves selective expression of a pan-ErbB-targeted CAR within a solid tumor, a microenvironment characterized by inadequate oxygen sup- ply. Using murine xenograft models, we demonstrate that, despite widespread expression of ErbB receptors in healthy organs, the approach provides anti-tumor efficacy without off-tumor toxicity. This dynamic on/off oxygen-sensing safety switch has the potential to facilitate unlimited expansion of the CAR T cell target repertoire for treating solid malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据